Key Points
- Insider sale: Arturo Md Molina sold 15,000 shares on March 26 at an average price of $104.79 for proceeds of $1,571,850, reducing his holding to 84,115 shares (a 15.13% decrease).
- Clustered insider selling: Multiple insiders (including the CFO and a board director) disclosed about 63,765 shares sold on March 26 — transactions worth several million dollars that may have contributed to near‑term selling pressure.
- Offsetting positives: The company announced favorable one‑year Phase 3 data for ICOTYDE and multiple analysts have raised price targets (average target ≈ $107.31, 13 Buys), while the stock trades near its 52‑week high with a $6.32B market cap.
Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) insider Arturo Md Molina sold 15,000 shares of the stock in a transaction dated Thursday, March 26th. The shares were sold at an average price of $104.79, for a total value of $1,571,850.00. Following the completion of the transaction, the insider owned 84,115 shares in the company, valued at approximately $8,814,410.85. The trade was a 15.13% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Arturo Md Molina also recently made the following trade(s):
- On Friday, January 23rd, Arturo Md Molina sold 13,151 shares of Protagonist Therapeutics stock. The stock was sold at an average price of $82.42, for a total value of $1,083,905.42.
- On Tuesday, January 27th, Arturo Md Molina sold 5,000 shares of Protagonist Therapeutics stock. The stock was sold at an average price of $82.00, for a total value of $410,000.00.
- On Tuesday, January 20th, Arturo Md Molina sold 9,514 shares of Protagonist Therapeutics stock. The stock was sold at an average price of $82.48, for a total transaction of $784,714.72.
Protagonist Therapeutics Stock Performance
Shares of PTGX opened at $98.97 on Friday. The company has a market capitalization of $6.32 billion, a price-to-earnings ratio of -48.28 and a beta of 2.23. The firm has a 50-day simple moving average of $88.99 and a 200-day simple moving average of $82.50. Protagonist Therapeutics, Inc. has a fifty-two week low of $39.60 and a fifty-two week high of $105.69.
Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last posted its quarterly earnings results on Wednesday, February 25th. The company reported ($0.69) earnings per share for the quarter, missing analysts' consensus estimates of ($0.53) by ($0.16). Protagonist Therapeutics had a negative net margin of 282.83% and a negative return on equity of 19.89%. The business had revenue of $7.44 million during the quarter, compared to analysts' expectations of $14.92 million. Equities research analysts forecast that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current year.
Institutional Investors Weigh In On Protagonist Therapeutics
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Farther Finance Advisors LLC increased its position in shares of Protagonist Therapeutics by 110.6% in the fourth quarter. Farther Finance Advisors LLC now owns 297 shares of the company's stock worth $26,000 after acquiring an additional 156 shares in the last quarter. Greenline Wealth Management LLC acquired a new stake in Protagonist Therapeutics in the fourth quarter valued at approximately $27,000. Salomon & Ludwin LLC bought a new stake in Protagonist Therapeutics in the third quarter worth $29,000. EverSource Wealth Advisors LLC raised its stake in shares of Protagonist Therapeutics by 138.9% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 540 shares of the company's stock valued at $36,000 after acquiring an additional 314 shares in the last quarter. Finally, Abich Financial Wealth Management LLC acquired a new stake in shares of Protagonist Therapeutics in the third quarter worth $62,000. Institutional investors and hedge funds own 98.63% of the company's stock.
Key Stories Impacting Protagonist Therapeutics
Here are the key news stories impacting Protagonist Therapeutics this week:
- Positive Sentiment: One‑year Phase 3 clinical data for ICOTYDE (icotrokinra) were presented at the 2026 AAD meeting showing durable skin clearance and a favorable safety profile for this once‑daily oral IL‑23 receptor targeted peptide, reinforcing ICOTYDE’s differentiated positioning in moderate‑to‑severe plaque psoriasis. AAD Presentation
- Positive Sentiment: An analyst price target was raised (reported as an 11.65% increase to $114.50), which signals at least one analyst firm sees more upside following recent data/updates. Analyst optimism can support longer‑term upside. Price Target Increase
- Neutral Sentiment: Industry/strategy commentary (ClearBridge / ClearBridge Small Cap Growth Strategy mention) discusses the company’s pipeline and potential; useful context but not an immediate catalyst. Industry Note
- Negative Sentiment: Multiple insiders (including the CFO Asif Ali, a board director Harold Selick, and insider Arturo Molina) sold shares on March 26 — approximately 63,765 shares disclosed across filings, representing several million dollars of stock sold. Large, clustered insider sales are being read negatively by the market and likely contributed to near‑term selling pressure. Insider SEC Filing
Analyst Ratings Changes
Several analysts have commented on PTGX shares. TD Cowen lifted their price target on Protagonist Therapeutics from $90.00 to $100.00 and gave the company a "buy" rating in a report on Thursday, February 26th. Barclays upped their target price on Protagonist Therapeutics from $113.00 to $119.00 and gave the stock an "overweight" rating in a research report on Thursday, March 19th. The Goldman Sachs Group lifted their price target on shares of Protagonist Therapeutics from $65.00 to $95.00 and gave the stock a "neutral" rating in a research note on Tuesday, March 3rd. JPMorgan Chase & Co. increased their target price on Protagonist Therapeutics from $95.00 to $106.00 and gave the company an "overweight" rating in a research note on Thursday, March 19th. Finally, Leerink Partners upped their price objective on Protagonist Therapeutics from $107.00 to $110.00 and gave the company an "outperform" rating in a research note on Thursday, March 19th. Thirteen investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $107.31.
Read Our Latest Research Report on PTGX
Protagonist Therapeutics Company Profile
(
Get Free Report)
Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist's approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.
Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn's disease.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
